STVNSTVNHealthcare · Medical Instruments & Supplies

STVN Stock Forecast: Stevanato Group SpA Price Predictions for 2026-2027

Last close, 20 Nov 2026
$16
−1.76% on the day

The 13 Wall Street analysts covering Stevanato Group SpA hold a median 12-month price target of $20 — +27.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 59 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$4.4B
Ticker Nerd rank
59/ 100
Median analyst target
$20
Analysts covering
13
Revenue$302.0M+7.9% y/y
Operating income$51.3M
Net income$23.0M
Free cash flow−$33.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
−17.7%
YTD
−21.9%
1Y
−25.8%
From 52W high
−33.0%
From 52W low
+18.5%
$13
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Stevanato Group SpA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
59/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
82
Volatility
70
Growth
67
Quality
65
Revisions
60
Issuance
57
Accruals
41
Momentum
32

Value (82): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (32): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

STVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$12$14$16$18$20$22$24$26Jan 26Apr 26Jul 26Oct 26STVNHigh $25Median $20Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
9
Buy
4
Hold
0
Sell
$16
Low
$20
Median
$25
High

The green dot is the last close — the median target sits +27.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
4 Nov 2026CitigroupMaintainsBuy$26 → $20
4 Nov 2026UBSMaintainsNeutral$23 → $16
4 Nov 2026William BlairDowngradeMarket Perform—
9 Sept 2026UBSMaintainsNeutral$28 → $23
16 June 2026TD CowenInitiatesBuy—
2 June 2026Wolfe ResearchAssumesOutperform$21
6 Mar 2026Morgan StanleyMaintainsEqual-Weight—
5 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026KeybancMaintainsOverweight—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Mar 2025UBSMaintainsNeutral—
13 Dec 2024B of A SecuritiesMaintainsBuy—
13 Dec 2024Wolfe ResearchInitiatesOutperform—
3 Dec 2024Morgan StanleyAssumesEqual-Weight$24 → $23
7 Aug 2024CitigroupMaintainsBuy—
15 July 2024Morgan StanleyMaintainsEqual-Weight—
22 Apr 2024Morgan StanleyMaintainsEqual-Weight—
25 Mar 2024Stephens & Co.ReiteratesOverweight—
1 Nov 2023JefferiesDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STVN.

Market Radar

This page is one stock. Monday covers all of them.

STVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

STVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Stevanato Group SpA returned −25.8% against +6.9% for the S&P 500, dividends included.

STVN vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26STVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−3.2%
Analysts raising
0
Analysts cutting
12
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.7×

Cheaper than 32% of US stocks

Price / sales
3.4×

Cheaper than 31% of US stocks

Price / book
2.4×

Cheaper than 37% of US stocks

EV / EBITDA
15.3×

Cheaper than 33% of US stocks

Growth & margins
Revenue growth (YoY)
7.6%

Higher than 48% of US stocks

Earnings growth (YoY)
16.0%

Higher than 55% of US stocks

Gross margin
28.7%

Higher than 32% of US stocks

Operating margin
18.0%

Higher than 76% of US stocks

Net margin
11.2%

Higher than 70% of US stocks

Returns & dividend
Return on equity
9.3%

Higher than 61% of US stocks

Return on assets
5.5%

Higher than 78% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stevanato Group SpA has a market value of $4.4B and an enterprise value of $5.2B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 7.9% year on year.

  • Net income over the same four quarters: $134.6M, a 11.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.48.

  • Free cash flow in the twelve months to 30 June 2026: −$30.7M.

  • Shares outstanding: 273.1M.

  • Trailing P/E: 26.7×; forward P/E: 21.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Stevanato Group SpA employs 6,010 people — $204K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

STVN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
STVNStevanato Group SpA$4.4B59
ICUIICU Medical, Inc.$4.3B95
MMEDMiniMed Group, Inc.$4.5B1
NVSTEnvista Holdings Corp.$3.7B96
MMSIMerit Medical Systems, Inc.$5.0B86
PLSEPulse Biosciences, Inc.$3.3B54
WRBYWarby Parker, Inc.$2.9B28

Take a look at STVN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Stevanato Group SpA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about STVN

What is the STVN stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Stevanato Group SpA have a median 12-month price target of $20, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STVN stock a buy right now?

Of the 13 analysts covering Stevanato Group SpA, 9 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stevanato Group SpA 59 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STVN?

As at 21 Nov 2026, Stevanato Group SpA ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (82 of 100).

Will STVN stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +27.8% from the last close, and Ticker Nerd's factor model ranks Stevanato Group SpA 59 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STVN stock forecast for 2030?

No analyst covering Stevanato Group SpA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.

How has STVN stock performed over the past year?

Stevanato Group SpA returned -25.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stevanato Group SpA do?

Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle.

Company

About Stevanato Group SpA.

Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle. Its portfolio includes containment systems such as vials, cartridges, syringes, and ampoules, alongside drug delivery devices, diagnostic consumables, analytical services, and medical devices. Stevanato Group also offers engineering capabilities through visual inspection, assembling, packaging, and glass-forming machinery, supporting manufacturing and packaging operations for biopharma customers. Headquartered in Piombino Dese, Italy, the company serves a global customer base across multiple healthcare and diagnostic markets.

CEO Mr. Franco Stevanato · 6,010 employees · Italy · https://www.stevanatogroup.com